Inhibitor Therapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
900 W Platt St Ste 200, Tampa, Florida, ...Website
www.inhibitortx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Inhibitor Therapeutics
Inhibitor Therapeutics, Inc. is a pharmaceutical development company dedicated to creating innovative therapies that inhibit the progression of cancerous and non-cancerous proliferation disorders. Their lead product, itraconazole, targets hereditary cancer syndromes, specifically Gorlins syndrome, which is classified as an orphan disease. The company focuses on repurposing already approved active pharmaceutical ingredients for new, clinically valuable, and patent-protected indications. Their intended clients include patients suffering from various cancer types, particularly those with unmet medical needs.Explore more
Inhibitor Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inhibitor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Inhibitor Therapeutics has new funding data
Product Launch: Get notified when Inhibitor Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Inhibitor Therapeutics
Check if Inhibitor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Inhibitor Therapeutics is spiking on competitors!
Click to see if Inhibitor Therapeutics had a recent Job posting/layoffs
Inhibitor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Inhibitor Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Inhibitor Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Inhibitor Therapeutics
Compare insights from companies similar to Inhibitor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Inhibitor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inhibitor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inhibitor Therapeutics.
Inhibitor Therapeutics Tech Stack
A closer look at the technologies used by Inhibitor Therapeutics
See more technologies
Inhibitor Therapeutics News & Media
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
Inhibitor Therapeutics (OTCQB: INTI) updates itraconazole PK study, highlights amorphous formulation and planned global patent filing.Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the treatment of Basal Cell Carcinomas in patients with Basal Cell Carcinoma Nevus Syndrome, otherwise known as Gorlin Syndrome. Inhibitor has allied with The Gorlin Syndrome Alliance and sought supportive guidance from the accomplished and highly-experienced members of its Scientific Advisory Board in effortsInhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
A critical milestone completed on the mission path of commercializing Itraconazole in numerous oncology indications. TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the...INHIBITOR Therapeutics Receives prostate cancer IND Clearance from FDA
TAMPA, Fla., Jan. 22, 2020 /PRNewswire/ -- INHIBITOR Therapeutics, Inc. (OTCQB: INTI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous and non-cancerous proliferation disorders, today...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inhibitor Therapeutics
Sign Up For FreeTo access detailed company insights
Inhibitor Therapeutics, Inc. is a pharmaceutical development company dedicated to creating innovative therapies that inhibit the progression of cancerous and non-cancerous proliferation disorders. Their lead product, itraconazole, targets hereditary cancer syndromes, specifically Gorlins syndrome, which is classified as an orphan disease. The compa... Read More
